CUE BIOPHARMA
Cue Biopharma (Cue) is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cells for the treatment of cancer and autoimmune disease. Cue biologics generate tailored immune responses in disease-relevant T cell populations by emulating the signals, or cues, delivered by the body’s antigen-presenting cells (APCs), and can potentially address any T cell-mediated disease. Through this platform approach, Cue has developed a portfolio of promising drug ... candidates with two lead programs currently approaching the clinic. Headquartered in Kendall Square, Cambridge, Massachusetts, Cue is led by a strong, experienced management team and scientific advisory board (SAB) with deep expertise in the design and clinical development of protein biologics, immunology, and immuno-oncology.
CUE BIOPHARMA
Industry:
Biopharma Biotechnology Health Care Medical Device
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.cuebiopharma.com
Total Employee:
11+
Status:
Active
Contact:
617-949-2680
Total Funding:
26.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Nginx
Similar Organizations
ALung Technologies
ALung Technologies develops medical gas exchange devices for the treatment of acute and chronic respiratory disorders.
Asklepios BioPharmaceutical
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders.
BioMarck Pharmaceuticals
BioMarck Pharmaceuticals develops new drugs for the treatment of pulmonary diseases.
CN Bio Innovations
CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases.
Fuse Medical
Fuse Medical distributes healthcare products and supplies to ambulatory surgical centers and hospitals.
Kypha
Kypha develops technology and clinical products to improve monitoring and treatment of autoimmune and inflammatory diseases.
NanoBio Designs
NanoBio Designs offers an efficient detection platform to verify the presence or absence and levels of targeted genetic markers in samples.
Sextant Therapeutics
Sextant is developing personalized cancer therapies that trigger the tumor to recruit the patient's own cancer-killing immune response.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Stereotaxis
Stereotaxis develops robotic cardiology instrument navigation systems that enhances the treatment of arrhythmias and coronary diseases.
Theravectys
Theravectys develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions.
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical focuses on the development of various products for the treatment of rare and ultra-rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
MDB Capital Group
MDB Capital Group investment in Series B - Cue Biopharma
MDB Capital Group
MDB Capital Group investment in Series A - Cue Biopharma
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-15 | Cue Biopharma Announces Appointment of Patricia Nasshorn as Chief Business Officer |
Official Site Inspections
http://www.cuebiopharma.com Semrush global rank: 4.72 M Semrush visits lastest month: 2.01 K
- Host name: 157.167.196.104.bc.googleusercontent.com
- IP address: 104.196.167.157
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Cue Biopharma"
About Us - Cue Biopharma
The innate sophistication of the immune system inspires us to engineer precision immunotherapies that transform patients lives. We have engineered and are developing a …See details»
Leadership - Cue Biopharma
Dan Passeri is a seasoned biotechnology executive with over 20 years of experience managing drug discovery and development programs as well as business development activities on …See details»
Investors - Cue Biopharma
May 15, 2025 During his time there he led Janssen’s Business Development organization to identify, execute, integrate and manage global licensing, mergers & acquisitions (M&A), …See details»
Board of Directors - Cue Biopharma
Dr. Frank Morich is a biopharmaceutical professional with more than 35 years of industry experience. He served on the board of directors for MorphoSys from 2015-2021 and Innate …See details»
News - Cue Biopharma
Contact 40 Guest Street, Boston, MA 02135 Tel 617-949-2680 General Inquiries [email protected]See details»
Cue Biopharma Announces Strategic Organizational Transition
Nov 14, 2024 For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn. Forward-Looking Statements This press release contains forward-looking …See details»
Cue Biopharma - LinkedIn
Cue Biopharma | 4,362 followers on LinkedIn. Cue Biopharma, a clinical-stage biopharmaceutical company is developing a novel class of therapeutic …See details»
Contact Us - Cue Biopharma
Cue Biopharma 40 Guest Street Boston, MA 02135 617-949-2680 General inquiries, please contact us at [email protected] Business Development inquiries, please contact us at …See details»
New collaboration to develop treatment for …
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn. Cautionary Note Regarding Forward-Looking Statements This press …See details»
Cue Biopharma Announces Strategic Prioritization of Autoimmune …
Headquartered inBoston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as …See details»
Cue Biopharma Enters into a Strategic Collaboration and Option ...
Feb 22, 2023 The Investor Relations website contains information about Cue Biopharma, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Cue Biopharma Inc - BIO International Convention 2025
Cue Biopharma™ is an immunotherapy company developing biologics engineered to selectively communicate with disease-relevant T cell subsets to treat cancer and autoimmune disease.See details»
Cue Biopharma, Inc. (Cue Biopharma, Inc.) - 药物管线_专利_临床试 …
Jun 15, 2025 了解Cue Biopharma, Inc. (Cue Biopharma, Inc.)公司的药物管线，治疗领域，技术平台，以及它的4项临床试验, 138篇新闻和1篇文献，疾病领域:免疫系统疾病，肿瘤，内分泌 …See details»
Cue Biopharma - Crunchbase Company Profile & Funding
Cue Biopharma is a developer of a productive platform for the treatment of cancer and autoimmune disease.See details»
Cue Biopharma - 2025 Company Profile & Team - Tracxn
Jul 27, 2025 Cue Biopharma - Biologics engineered to selectively activate disease-relevant immune cells to treat cancer and autoimmune diseases.. Public Company. Raised a total …See details»
Cue Biopharma - Craft
Oct 29, 2024 Cue Biopharma is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cells for the treatment of cancer and autoimmune …See details»
Cue Biopharma - Company Profile & Staff Directory | ContactOut
Cue Biopharma is a Biotechnology company located in 40 Guest Street, Boston, Massachusetts 02135, US with 47 employees. Access Cue Biopharma's email format and Cue Biopharma …See details»
Cue Biopharma (CUE) Stock Price & Overview
2 days ago A detailed overview of Cue Biopharma, Inc. (CUE) stock, including real-time price, chart, key statistics, news, and more.See details»
Boehringer Ingelheim and Cue Biopharma partner to develop
Apr 15, 2025 For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn. Cautionary Note Regarding Forward-Looking StatementsSee details»
Cue Biopharma 2025 Company Profile: Stock Performance
Information on stock, financials, earnings, subsidiaries, investors, and executives for Cue Biopharma. Use the PitchBook Platform to explore the full profile.See details»